CJC-1295
OtherAlso known as Modified GRF (1-29), CJC-1295 without DAC
Evidence tier
Multiple human trials
2 human trials
- Researched since
- 2005
- Publications
- 32
- Mean purity
- 99.5%
- Vendors listing
- 19
Simple Peptide shows the highest mean assayed purity for CJC-1295 at 99.8% across 2 lot records. Purity figures below come from the certificates named in each row.
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 2005 — 21 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
32 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
Mean assayed purity 99.5% across 12 certificates
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
±0.37 pts purity across lots, mean label deviation 18.5%
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
19 of 19 listing vendors publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
12 of 12 certificates from a recognised independent lab
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is CJC-1295?
A synthetic analogue of growth hormone releasing hormone. Two distinct forms circulate under similar names — with and without a drug affinity complex — and vendors are not consistent about which they list. This index records the form named on the certificate rather than the form named in the product title.
Studied in published research for growth-hormone release, recovery and body composition.
Regulatory status
Labeled by vendors for laboratory research use only. Not an approved medicine.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
Published work is early-phase and preclinical. The naming ambiguity between the two forms is itself a documentation problem, and is one of the things the certificate records on this site are useful for checking.
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults — The Journal of clinical endocrinology and metabolism (2006)
Peer-reviewed article indexed in PubMed, published in The Journal of clinical endocrinology and metabolism (2006).
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews (2026)
Peer-reviewed article indexed in PubMed, published in Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews (2026).
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians — The American journal of sports medicine (2026)
Peer-reviewed article indexed in PubMed, published in The American journal of sports medicine (2026).
- A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS — Drug testing and analysis (2019)
Peer-reviewed article indexed in PubMed, published in Drug testing and analysis (2019).
- Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions — Substance use & misuse (2016)
Peer-reviewed article indexed in PubMed, published in Substance use & misuse (2016).
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — Sports medicine (Auckland, N.Z.) (2026)
Peer-reviewed article indexed in PubMed, published in Sports medicine (Auckland, N.Z.) (2026).
- An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma — Drug testing and analysis (2019)
Peer-reviewed article indexed in PubMed, published in Drug testing and analysis (2019).
- Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse — American journal of physiology. Endocrinology and metabolism (2006)
Peer-reviewed article indexed in PubMed, published in American journal of physiology. Endocrinology and metabolism (2006).
Indexed studies2 human-evidence of 2
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults — Human — controlled trial, 2006
Therapeutic use of GHRH to enhance GH secretion is limited by its short duration of action. The objective of this study was to examine the pharmacokinetic profile, pharmacodynamic effects, and safety of CJC-1295, a long-acting GHRH analog. The study design was two randomized, placebo-controlled, double-blind, ascending dose trials with durations of 28 and 49 d. The study was performed at two investigational sites. Healthy subjects, ages 21-61 yr, were studied. CJC-1295 or pla…
- Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog — Human — controlled trial, 2006
Pulsatile GH secretion is considered important for many of the hormone's physiological effects. Short-term GHRH infusions enhance GH pulsatility and increase IGF-I, but the short GHRH half-life limits its therapeutic use. A synthetic GHRH analog (CJC-1295) that binds permanently to endogenous albumin after injection (half-life = 8 d) stimulates GH and IGF-I secretion in several animal species and in normal human subjects and enhances growth in rats. Our objective was to asses…
Evidence digest
What the research on CJC-1295 actually shows
The indexed literature on CJC-1295 includes human clinical or observational records (2 human-clinical or observational records). This digest describes the shape of that evidence and links the records behind it. It does not judge whether CJC-1295 is safe or effective for any purpose, and nothing here is medical advice — the material sold by the vendors in this index is labeled for laboratory research use only.
3 things the literature does not establish →
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.
Vendor comparison
| Vendor | Score here | Price / mg | Certificates | Mean purity | Label deviation | Get it |
|---|---|---|---|---|---|---|
| CuroISO/IEC 17025 | 93.877% | — | 1 | 99.7% | 72.0% | |
| Ascend ScienceISO/IEC 17025 | 90.291% | — | 2 | 99.5% | 40.9% | |
| Protide Health | 88.994% | $7.50 (75%) | 0 | — | — | |
| American PeptidesISO/IEC 17025 | 84.5100% | $11.00 (110%) | 0 | — | — | |
| Ascension Peptides | 82.186% | $8.00 (80%) | 2 | 98.9% | 1.1% | |
| Good Science Bio | 79.275% | $4.50 (45%) | 0 | — | — | |
| Improved Peptides | 7789% | $5.90 (59%) | 0 | — | — | |
| Licensed Peptides | 7789% | — | 1 | 99.8% | 3.6% | |
| NeuroLabs Research | 74.186% | $12.00 (120%) | 0 | — | — | |
| Modern AminosISO/IEC 17025 | 74100% | $20.00 (200%) | 2 | 99.6% | 13.6% | |
| Eternal Peptides | 7365% | $6.00 (60%) | 0 | — | — | |
| Northline LabsISO/IEC 17025 | 72.393% | $20.00 (200%) | 2 | 99.4% | 3.2% | |
| Mile High Compounds | 71.194% | $6.00 (60%) | 0 | — | — | |
| GenX Peptides | 71.168% | $8.50 (85%) | 0 | — | — | |
| Simple Peptide | 7189% | $18.00 (180%) | 2 | 99.8% | 14.2% | |
| Hydro Research PeptidesISO/IEC 17025 | 69.289% | $16.00 (160%) | 0 | — | — | |
| Evolve Peptides | 6867% | $8.98 (90%) | 0 | — | — | |
| ZC Labs | 63.284% | $20.00 (200%) | 0 | — | — | |
| Extreme Peptides | 56.982% | $15.50 (155%) | 0 | — | — |
Certificate records
| Vendor | Lot | Tested | Lab | Labeled | Assayed | Discrepancy | Purity | Source |
|---|---|---|---|---|---|---|---|---|
| Curo | CND10ZO626 | BTLabs | 10 mg | 17.2 mg | 72.0% | 99.7% | Vendor-published | |
| Ascend Science | AS-CD5 | Kovera Labs and/or ILS Labs | 10 mg | 6.39 mg | 36.1% | 99.4% | Vendor-published | |
| Ascend Science | AS-CND5 | Kovera Labs and/or ILS Labs | 10 mg | 5.43 mg | 45.7% | 99.5% | Vendor-published | |
| Northline Labs | NLL-5723262 | ILS Laboratories | 5 mg | 5.26 mg | 5.2% | 99.4% | Vendor-published | |
| Simple Peptide | CJND10-062026-2 | Analysis FreedomDiagnostics | 10 mg | 10.27 mg | 2.7% | 99.9% | Vendor-published | |
| Ascension Peptides | 13-01260229 | MZ Biolabs | 5 mg | 4.96 mg | 0.7% | 99.3% | Vendor-published | |
| Northline Labs | NLL-5820822 | ILS Laboratories | 10 mg | 9.88 mg | 1.2% | 99.3% | Vendor-published | |
| Simple Peptide | CJCD05-032026-1 | Freedom Diagnostics | 5 mg | 6.28 mg | 25.6% | 99.7% | Vendor-published | |
| Modern Aminos | BX-P-E3F2 | Freedom Diagnostics Testing | 5 mg | 6.31 mg | 26.2% | 99.8% | Vendor-published | |
| Modern Aminos | BX-P-D3F4 | Freedom Diagnostics Testing | 2.18 mg | 2.16 mg | 0.9% | 99.5% | Vendor-published | |
| Licensed Peptides | LP02202016 | Vanguard Laboratory | 60 mg | 57.87 mg | 3.6% | 99.8% | Vendor-published | |
| Ascension Peptides | 2025-08-07 | MZ Biolabs | 10 mg | 9.84 mg | 1.6% | 98.4% | Vendor-published |